News
CMXHF
90.00
NaN%
--
CSL Updates Market on Progress of Ongoing On‑Market Share Buy‑Back
TipRanks · 21h ago
Jarden Remains a Buy on CSL (CMXHF)
TipRanks · 1d ago
CSL Ramps Up On-Market Buy-Back With Nearly 6 Million Shares Repurchased
TipRanks · 4d ago
CSL Updates Market on Progress of Ongoing Share Buy-Back
TipRanks · 04/23 22:53
Eurazeo unit Kurma Partners closes Biofund IV at EUR 215 million
PUBT · 04/23 12:34
CSL (CMXHF) Gets a Hold from Ord Minnett
TipRanks · 04/22 01:36
CSL Records Lapse of Conditional Rights in Minor Capital Adjustment
TipRanks · 04/19 22:58
Ord Minnett Sticks to Its Hold Rating for CSL (CMXHF)
TipRanks · 04/13 05:15
BUZZ-Jefferies trims CSL's PT as growth in key markets falls short of 'stellar'
Reuters · 04/12 19:22
Analysts’ Opinions Are Mixed on These Healthcare Stocks: CSL (OtherCMXHF), Fortrea Holdings Inc. (FTRE) and Olympus (OtherOCPNF)
TipRanks · 04/12 12:20
Jarden Sticks to Its Buy Rating for CSL (CMXHF)
TipRanks · 04/09 23:37
Bell Potter Sticks to Their Hold Rating for CSL (CMXHF)
TipRanks · 04/09 01:37
BUZZ-Citi sees strong quarterly growth with likely cost impact for Resmed
Reuters · 04/08 19:29
CSL Posts Daily Update on Ongoing On-Market Share Buy-Back
TipRanks · 04/07 23:02
BUZZ-Australia's CSL gains on US tariff relief on key product imports
Reuters · 04/07 02:40
BRIEF-CSL Notes Announcement By United States Administration On 2 April
Reuters · 04/07 02:10
Analysts Have Conflicting Sentiments on These Healthcare Companies: CSL (OtherCMXHF) and Telix Pharmaceuticals (OtherTLPPF)
TipRanks · 04/07 01:40
CSL Sees Limited Impact From New U.S. Drug Tariffs, Expects Fluad Duties to Fall
TipRanks · 04/06 23:11
CSL Reports Daily Progress on Ongoing On‑Market Share Buy‑Back
TipRanks · 04/01 22:44
CSL Updates Market on Ongoing On-Market Share Buy-Back
TipRanks · 04/01 02:51
More
Webull provides a variety of real-time CMXHF stock news. You can receive the latest news about CSL through multiple platforms. This information may help you make smarter investment decisions.
About CMXHF
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.